首页> 外文OA文献 >An Exploratory Analysis of the Association Between EORTC-QLQ C30 Domains and Progression Free/Overall Survival in Advanced Melanoma After 12 Weeks of Treatment on Ipilimumab Compared to Gp100 in a Phase III Clinical Trial

【2h】

An Exploratory Analysis of the Association Between EORTC-QLQ C30 Domains and Progression Free/Overall Survival in Advanced Melanoma After 12 Weeks of Treatment on Ipilimumab Compared to Gp100 in a Phase III Clinical Trial

机译：在III期临床试验期间，在III期临床试验中对IPILIMIMAB治疗12周后ETTC-QLQ C30结构型和进展自由/整体存活率的探索性分析。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
D. Lee; B. Harvey; A.F. Gaudin; B. Gueron; B. Bregman; C. Lebbe; F. Bonnetain; I. Borget;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma [J] . Paolo Antonio Ascierto, Michelle Del Vecchio, Andrzej Mackiewicz, Journal for ImmunoTherapy of Cancer . 2020,第1期

机译：第III期试验中的5年后的整体存活率将IPILIMIMAB 10 mg / kg与3 mg / kg进行高级黑素瘤的患者
2. Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma [J] . Journal for ImmunoTherapy of Cancer . 2020,第2期

机译：矫正：在第III期试验中，5年后的总生存率将Ipilimumab 10 mg / kg与3 mg / kg进行高级黑素瘤的患者
3. Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial [J] . Maio Michele, Grob Jean-Jacques, Aamdal Steinar, Journal of Clinical Oncology . 2015,第10期

机译：在III期试验中接受伊匹木单抗联合达卡巴嗪的初次治疗的晚期黑色素瘤患者的五年生存率
4. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma [O] . Paolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, 2020

机译：第III期试验中的5年后的整体存活率将IPILIMIMAB 10 mg / kg与3 mg / kg进行高级黑素瘤的患者
5. Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer [O] . Masayuki Aboshi, Masayuki Kaneko, Mamoru Narukawa 2014

机译：晚期非小细胞肺癌一线治疗临床试验中影响总生存与无进展生存之间关系的因素

An Exploratory Analysis of the Association Between EORTC-QLQ C30 Domains and Progression Free/Overall Survival in Advanced Melanoma After 12 Weeks of Treatment on Ipilimumab Compared to Gp100 in a Phase III Clinical Trial

著录项

引文网络

相似文献

相关主题

期刊订阅